Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Benkert

Showing results (71-80 of 135) with videos related to

Pageof 14
Sort By:
Therapeutic Advances in Neurological Disorders|July 22, 2025
Investigation of the association of serum GFAP and NfL with brain and upper cervical MRI volumes in AQP4-IgG-positive NMOSD and MOGADPatrick Schindler, Ulrike Grittner, Rebekka Rust, et al.
Clinical Chemistry and Laboratory Medicine|December 17, 2025
Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patientsJustina Dargvainiene, Antje Torge, Klaus-Peter Wandinger, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 26, 2022
High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosisMartin Diebold, Edoardo Galli, Andreas Kopf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 4, 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-studyXavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, et al.
Journal of Neurology|April 10, 2026
Plasma neurofilament light chain and glial fibrillary acidic protein in the differential diagnosis of acute vertigo in the emergency departmentMelanie Haidegger, Natalie Berger, Simon Fandler-Höfler, et al.
Brain and Behavior|April 30, 2024
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosisJannis Müller, Izanne Roos, Tomas Kalincik, et al.
Neurology|February 13, 2020
Blood neurofilament light levels segregate treatment effects in multiple sclerosisBénédicte Delcoigne, Ali Manouchehrinia, Christian Barro, et al.
Annals of Neurology|December 30, 2020
Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019Raoul Sutter, Lisa Hert, Gian Marco De Marchis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 5, 2021
Increased Serum Neurofilament Light and Thin Ganglion Cell-Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple SclerosisTing-Yi Lin, Viktoriya Vitkova, Susanna Asseyer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MSJens Kuhle, Nadia Daizadeh, Pascal Benkert, et al.
Pageof 14

Showing results (71-80 of 135) with videos related to

Sort By:
Pageof 14
Therapeutic Advances in Neurological Disorders|July 22, 2025
Investigation of the association of serum GFAP and NfL with brain and upper cervical MRI volumes in AQP4-IgG-positive NMOSD and MOGADPatrick Schindler, Ulrike Grittner, Rebekka Rust, et al.
Clinical Chemistry and Laboratory Medicine|December 17, 2025
Comparative analysis of three platforms for serum NfL quantification in healthy controls and MS patientsJustina Dargvainiene, Antje Torge, Klaus-Peter Wandinger, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 26, 2022
High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosisMartin Diebold, Edoardo Galli, Andreas Kopf, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 4, 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-studyXavier Montalban, Karolina Piasecka-Stryczynska, Jens Kuhle, et al.
Journal of Neurology|April 10, 2026
Plasma neurofilament light chain and glial fibrillary acidic protein in the differential diagnosis of acute vertigo in the emergency departmentMelanie Haidegger, Natalie Berger, Simon Fandler-Höfler, et al.
Brain and Behavior|April 30, 2024
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosisJannis Müller, Izanne Roos, Tomas Kalincik, et al.
Neurology|February 13, 2020
Blood neurofilament light levels segregate treatment effects in multiple sclerosisBénédicte Delcoigne, Ali Manouchehrinia, Christian Barro, et al.
Annals of Neurology|December 30, 2020
Serum Neurofilament Light Chain Levels in the Intensive Care Unit: Comparison between Severely Ill Patients with and without Coronavirus Disease 2019Raoul Sutter, Lisa Hert, Gian Marco De Marchis, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 5, 2021
Increased Serum Neurofilament Light and Thin Ganglion Cell-Inner Plexiform Layer Are Additive Risk Factors for Disease Activity in Early Multiple SclerosisTing-Yi Lin, Viktoriya Vitkova, Susanna Asseyer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 11, 2021
Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MSJens Kuhle, Nadia Daizadeh, Pascal Benkert, et al.
Pageof 14